|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 12,059,409 (Sustained-Release Hydrogel-Forming Tablet; PEG + PEO; USP Dissolution Limits)
US 12,059,409 is a composition-of-matter style formulation patent centered on a specific API identity, a sustained-release hydrogel-forming tablet matrix built from polyethylene oxide (PEO) of defined molecular weight ranges, and a PEG additive with defined water solubility and dissolution-performance criteria measured in USP dissolution testing (900 mL, pH 6.8, 200 rpm). The claim set is narrow on polymer chemistry and performance metrics but provides multiple fallback positions through PEO molecular-weight subranges and PEG species selections, anchored by dissolution cutoffs at 1.5 hours (≤39% dissolved) and 7 hours (≥75% dissolved).
What does US 12,059,409 claim cover for sustained-release hydrogel-forming tablets?
Claim 1 defines the core protected subject matter: a tablet containing (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide (the API), in a sustained release hydrogel-forming formulation comprising:
- Drug amount: 10 mg to 200 mg
- Polymer system: hydrogel-forming polymer = polyethylene oxide
- Average molecular weight: 200,000 to 7,000,000
- Additive: polyethylene glycol (PEG)
- Water solubility requirement: at least 0.1 g/mL at 20 ± 5°C
- Drug dissolution constraints (USP method):
- ≤39% dissolved after 1.5 hours
- ≥75% dissolved after 7 hours
- Test conditions: USP buffer, pH 6.8; 900 mL; paddle 200 rpm
How to read the scope: even if a competitor uses the same API and includes PEO/PEG, infringement depends on meeting all of the claim elements simultaneously, especially:
- the PEO molecular weight range,
- PEG identity and solubility threshold, and
- the dissolution performance thresholds under the specified USP conditions.
Key claim elements that drive infringement risk
- API stereochemistry and identity: (R) configuration and the exact anilide chemical name.
- Dosage form: “tablet” with a hydrogel-forming sustained release formulation (not a capsule, not an implant, not a solution).
- Polymer identity: polyethylene oxide (PEO) specifically (not other hydrogel-formers like HPMC, Carbopol, PVP/VA crosspolymers, alginates, Eudragit variants).
- Polymer MW gate: 200,000 to 7,000,000 average MW.
- Additive identity: PEG (polyethylene glycol), with solubility ≥0.1 g/mL.
- Performance gate: USP dissolution profile with explicit % dissolved at specified timepoints.
Dependent claims 2–15: what fallback positions exist?
The dependent claims refine two axes while preserving the same overall dissolution and matrix framework from claim 1.
PEO molecular-weight subranges (claims 2–5, 2–4; plus narrowed at 5)
- Claim 2: PEO MW 200,000 to 5,000,000
- Claim 3: PEO MW 1,000,000 to 4,000,000
- Claim 4: PEO MW 2,000,000 to 4,000,000
- Claim 5: PEO MW 2,000,000 (single value)
These are not additive across each other; they are separate dependent narrowing fallbacks.
PEG species selection (claims 6–15; PEG 400, 1500, 4000, 6000, 20000)
- Claim 6: PEG selected from PEG 400 / 1500 / 4000 / 6000 / 20000
- Claims 7–10: each tied to the respective PEO MW subranges of claims 2–5 (same PEG list)
- Claim 11: PEG 6000
- Claims 12–15: PEG 6000 tied to PEO MW subranges of claims 2–5
Dependent claims 16–29: what do they add?
Claims 16–29 mostly restate the drug amount range (10 mg to 200 mg) and map to the same dependent structures (claims 17–29) by referencing specific PEO MW and/or PEG selection tiers as already defined in claims 2–15.
Practical effect: claims 16–29 act as additional coverage for the same matrix embodiments while locking in the dosage range and linking to the polymer/additive subranges.
How does the USP dissolution testing language limit claim scope and design-around options?
Claim 1’s dissolution profile is the operational boundary. The dissolution “gate” is defined by:
- timepoints: 1.5 hours and 7 hours
- measured quantity: % drug dissolved
- threshold values: ≤39% at 1.5h and ≥75% at 7h
- test setup: 900 mL, buffer pH 6.8, USP paddle 200 rpm
What this means for a generic or formulation competitor
To avoid infringement, a designer must disrupt at least one mandatory element. Typical friction points:
- miss the PEO MW range (e.g., choose PEO outside 200,000–7,000,000 or outside the dependent subranges),
- use a non-PEO hydrogel-former,
- use PEG with water solubility below the 0.1 g/mL requirement,
- or deliberately alter the dissolution curve such that it crosses either:
- exceed 39% at 1.5 hours, or
- fall below 75% at 7 hours.
Because the patent ties to USP pH 6.8 and 200 rpm paddle dissolution in 900 mL, a competitor’s dissolution method that deviates from these conditions could alter measured performance, but claim language is written to enforce the specified measurement scheme. For infringement analysis, regulators and litigators typically treat stated test parameters as part of the claim.
Potential ambiguity that still constrains scope
The claim specifies “drug dissolution rate” but uses explicit % dissolved thresholds. In practice, those are direct numerical dissolution endpoints. The operational constraint is clear: the formulation must achieve the stated release behavior under the stated test.
What specific chemical and formulation limitations exist (API, polymer, additive, dosage form)?
API limitation
- Exact stereoisomer and chemical identity: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide.
This is not “any salt” alone; it is the compound (or a pharmaceutically acceptable salt) as the API.
Polymer limitation
- Hydrogel-forming polymer = polyethylene oxide
- polymer MW average required:
- claim 1: 200,000 to 7,000,000
- dependent claims further narrow (200k–5M; 1M–4M; 2M–4M; 2M)
Additive limitation
- Additive = polyethylene glycol (PEG)
- PEG must meet water solubility ≥0.1 g/mL at 20 ± 5°C (claim 1)
- dependent claims narrow PEG to specific molecular-weight PEG species:
- PEG 400, 1500, 4000, 6000, 20000
- and explicitly PEG 6000 in claims 11–15
Dosage form limitation
- “tablet” and a sustained-release hydrogel-forming formulation.
This excludes many alternative oral sustained-release formats unless they are argued to meet “tablet” and the hydrogel-forming sustained release formulation structure.
How many claim “design spaces” are there across the dependent claim matrix?
At the claim-structure level, the patent defines a combinatorial design space via:
- PEO MW tier: (claim 1 broad; plus dependent tiers 2–5)
- PEG species tier: (claim 6 list; plus dependent claim 11 PEG 6000)
- Dosage amount: (10–200 mg)
Matrix decomposition (conceptual)
- Base (claim 1): PEO MW 200k–7M + PEG (solubility ≥0.1 g/mL) + USP dissolution gates.
- PEO subranges (claims 2–5): each locks the PEO MW to a narrower band.
- PEG subchoices (claims 6–10): restrict PEG to specific listed MWs.
- PEG 6000 (claims 11–15): further narrows PEG identity to PEG 6000.
- Dosage range restated in claims 16–29 (linked to the relevant tiered embodiments).
Bottom line: coverage strength is concentrated in formulations that land inside the PEO MW windows and that reproduce the specified dissolution profile. The dependent claims increase enforceability leverage by giving multiple narrower “entry points” where an accused formulation still falls within a subrange.
What patents compete with US 12,059,409 in sustained-release PEO/PEG tablets, and how do those typical estates compare?
No competing patent list can be produced from the provided input alone. Without specific bibliographic metadata for US 12,059,409 (priority date, assignee, full specification, examiner classification, family members) and without access to the full patent record, it is not possible to generate a defensible “landscape” of other relevant patents by number, jurisdiction, or claim overlap.
Accordingly, this analysis confines itself to the scope created by the claim text you provided.
What litigation and Orange Book questions matter for US 12,059,409?
No Orange Book listing, FDA approval context, or Paragraph IV history can be derived from the claim text alone. Patent status, listed patents, and litigation posture require dossier-level facts (drug reference product, NDA/BLA number, listed patent numbers and expiration dates, settlements, and court filings).
Accordingly, this analysis does not assert any Orange Book status, exclusivity timelines, or litigation events.
How strong is the claim set for enforcement under US claim construction norms?
Strength drivers
- Tight formulation specificity: requires exact API identity (with stereochemistry), PEO hydrogel polymer, PEG additive, and defined molecular weight ranges.
- Objective performance endpoints: dissolution thresholds at fixed timepoints under fixed test conditions.
- Multiple dependent fallbacks: PEO MW and PEG identity narrows give multiple ways for the patentee to argue coverage if an accused formulation matches a subrange.
Main enforcement constraint
- Narrow polymer/additive framework: a formulation that uses a different hydrogel-forming polymer or a different additive strategy could avoid coverage even if dissolution behavior matches.
Design-around pressure point
- The dissolution gates are especially potent. Even modest changes to gel strength, hydration kinetics, PEG/PEO ratio, or tablet geometry that shift % dissolved at 1.5 hours above 39% or depress 7-hour release below 75% can break the claim.
Key claim-by-claim “scope map” (from the provided claims only)
| Claim |
API identity/dose |
Polymer (PEO) MW |
Additive (PEG) |
Dissolution gates (USP 900 mL pH 6.8, 200 rpm) |
| 1 |
10–200 mg; (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or salt |
200,000–7,000,000 |
PEG; solubility ≥0.1 g/mL (20 ± 5°C) |
≤39% at 1.5 h; ≥75% at 7 h |
| 2 |
same |
200,000–5,000,000 |
PEG as in claim 1 |
same |
| 3 |
same |
1,000,000–4,000,000 |
PEG as in claim 1 |
same |
| 4 |
same |
2,000,000–4,000,000 |
PEG as in claim 1 |
same |
| 5 |
same |
2,000,000 |
PEG as in claim 1 |
same |
| 6 |
same |
as in claim 1 |
PEG = PEG 400/1500/4000/6000/20000 |
same |
| 7 |
same |
as in claim 2 |
PEG = PEG 400/1500/4000/6000/20000 |
same |
| 8 |
same |
as in claim 3 |
PEG = PEG 400/1500/4000/6000/20000 |
same |
| 9 |
same |
as in claim 4 |
PEG = PEG 400/1500/4000/6000/20000 |
same |
| 10 |
same |
as in claim 5 |
PEG = PEG 400/1500/4000/6000/20000 |
same |
| 11 |
same |
as in claim 1 |
PEG = PEG 6000 |
same |
| 12 |
same |
as in claim 2 |
PEG = PEG 6000 |
same |
| 13 |
same |
as in claim 3 |
PEG = PEG 6000 |
same |
| 14 |
same |
as in claim 4 |
PEG = PEG 6000 |
same |
| 15 |
same |
as in claim 5 |
PEG = PEG 6000 |
same |
| 16 |
10–200 mg (explicit) |
as in claim 1 |
as in claim 1 |
same |
| 17 |
10–200 mg (explicit) |
as in claim 2 |
as in claim 2 |
same |
| 18 |
10–200 mg (explicit) |
as in claim 3 |
as in claim 3 |
same |
| 19 |
10–200 mg (explicit) |
as in claim 4 |
as in claim 4 |
same |
| 20–29 |
10–200 mg (explicit) with linked PEO MW/PEG tiers per their dependency |
tied per dependency |
tied per dependency |
same |
Key Takeaways
- US 12,059,409 claim scope is defined by a specific API plus a PEO-based sustained-release hydrogel tablet with PEG additive and USP dissolution performance gates (≤39% at 1.5 hours; ≥75% at 7 hours in 900 mL pH 6.8 at 200 rpm).
- Dependent claims strengthen enforcement by adding PEO molecular weight subranges (including a single-value PEO 2,000,000) and PEG species selection, with a dedicated PEG 6000 path.
- The claims create clear design-around levers: use a different hydrogel polymer, use PEG outside the specified identity/solubility constraint, adjust PEO MW outside the ranges, or shift dissolution outside the stated thresholds under the specified USP test conditions.
FAQs
-
Do US 12,059,409 claims cover PEO-based capsules or only tablets?
The claims recite “a tablet,” so the protected form is a tablet within the claim language.
-
If dissolution matches in one medium, does that avoid infringement?
The claim requires the specified USP dissolution conditions (900 mL, pH 6.8, 200 rpm) and the numeric thresholds at 1.5 and 7 hours.
-
Which limitation is usually the hardest to design around: PEO MW or dissolution endpoints?
The dissolution endpoints are explicit performance constraints tied to defined test parameters, making them a direct infringement gate.
-
Is PEG 6000 explicitly covered even when PEO MW is 2,000,000?
Yes. Claims 15 and 5-linked structures identify PEG 6000 with the PEO MW subrange that includes PEO 2,000,000.
-
Can a different hydrogel-forming polymer avoid the patent?
Claim 1 requires the hydrogel-forming polymer to be polyethylene oxide, so switching the hydrogel polymer is a primary potential design-around route.
References
- US Patent 12,059,409, claim text provided in the prompt.
More… ↓
⤷ Start Trial
|
